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 i 
Abstract 
 
Lipoprotein associated phospholipase A2 (Lp-PLA2) is a biomarker of several inflammatory 
diseases and syndromes. An elevated Lp-PLA2 level is associated with unstable atherosclerotic 
plaques. Bound to plasma lipoproteins (LDL and HDL), Lp-PLA2 prevents the formation of 
biologically active oxidized phospholipids on their surface such as oxidized 
phosphatidylcholine (oxPC). Nevertheless, the products of Lp-PLA2 action, 
lysophosphatidylcholine (LPC) and non-esterified fatty acids (NEFA) are both known to 
aggravate inflammation. 
Thus, understanding the metabolism of Lp-PLA2 could help us better understand its role in 
plaque formation, as studies have shown high expression of Lp-PLA2 and LPCs in unstable 
plaques. Moreover, studies showed correlation between increased Lp-PLA2 mass and activity 
and increased risk of coronary artery disease, stroke, and death. The inhibition of Lp-PLA2 
with a small molecule, Darapladib, has not demonstrated benefit in reduction of cardiovascular 
events in two clinical studies.  
Here, the first chapter will focus on Lp-PLA2 and cardiovascular disease in man, highlighting 
the latest updates in the literature. The second and third chapters will introduce experimental 
work on Lp-PLA2 in the setting of acute coronary syndrome. 
 
Keywords : Lp-PLA2, Lipoprotein-associated phospholipase A2, PAF-AH, platelet activating 
factor acetyl hydrolase, acute coronary syndrome, ACS, cardiovascular diseases, HDL, LDL 
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Résumé 
La phospholipase A2 liée aux lipoprotéines (Lp-PLA2) est une biomarqueur de 
plusieurs maladies inflammatoires et une niveau sérique élevé est associé à l’instabilité de la 
plaque artérioscléreuse. Comme son nom l’indique, la Lp-PLA2 est liée aux lipoprotéines 
plasmatiques (LDL et HDL) et son rôle est de prévenir l’accumulation de phospholipides 
oxidés a la surface des lipoprotéines. Toutefois, les produits de dégradation des phospholipides 
oxidés par la Lp-PLA2 - le lysophosphatidyl choline par les acides gras oxidés peuvent aussi 
promouvoir l’inflammation.  
Mieux comprendre le métabolisme de la Lp-PLA2 pourrait nous permettre de mieux 
apprécier son rôle dans la formation d’une plaque artérioscléreuse instable, car des études 
antérieures ont démontré une forte expression de la Lp-PLA2 dans la plaque. De plus, il existe 
une forte corrélation entre les niveaux et l’activité  plasmatiques de la Lp-PLA2 et la maladie 
coronarienne, les accidents cérébraux-vasculaires et la mortalité cardiaque. L’inhibition de la 
Lp-PLA2 avec une petite molécule, le darapladib, n’a pas démontré de bénéfice sur les 
évènements cardiovasculaires dans deux études cliniques.  
Cette thèse présentera d’abord une revue de la littérature sur la Lp-PLA2 et les 
maladies cardiovasculaires et les deuxième et troisième chapitres, une étude clinique réalisée 
sur des patients avec un syndrome coronarien aigu.  
Mots-clés : Phospholipase A2 liée aux lipoprotéines (Lp-PLA2); Facteur d’activation des 
plaquettes (PAF); acyl hydrolase (AH); syndrome coronarien aigu (ACS); lipoprotéines de 
haute densité (HDL); lipoprotéines de basse densité (LDL). 
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Chapter I: Introduction 
 
 
 
 
 
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): a brief 
introduction 
 
 
 
  
 
1.1 Introduction  
 
Cardiovascular diseases are the leading cause of death worldwide. Over decades, studies 
aimed to identify and evaluate cardiovascular risk in individuals. The Framingham Heart 
Study is probably the frontrunner in this field. Launched in 1948, Framingham’s first cohort 
included more than 5,000 participants, and followed in recruiting around 9,000 subjects from 
their offspring in a second and a third cohorts (1971 and 2002) for a total of more than 14,000 
participants. Today, our clinical guidelines include “traditional” modifiable risk factors for 
cardiovascular diseases: smoking, high cholesterol levels, diabetes, hypertension, obesity, low 
physical activity and unhealthy diet. Targeting those risk factors by clinicians has resulted in a 
50% reduction in age adjusted mortality rates in the US over a 50-year period. In Canada, we 
see a glimpse of progress as cardiovascular diseases (for the first time) ranked second instead 
of first as a leading cause of death in 2008. This has largely been confirmed in many 
observational studies, especially the INTERHEART study. 1-4 However, an observational 
study by the National Registry of Myocardial Infarction (NRMI) showed that out of a total of 
542,008 patients presented with a first acute myocardial infarction between 1994 and 2006, an 
overall 78,103 (14.4%) had none of the risk factors mentioned above, hence the need for 
additional biomarkers of cardiovascular risk. 5 
Coronary artery disease (CAD) is overwhelmingly caused by atherosclerosis, a process that 
involves long-term chronic inflammation of the arteries. Thus, the relationship between 
inflammation, atherosclerosis and the high incidence of cardiovascular diseases (CVD) has 
been extensively studied. The inflammatory process is triggered by a combination of lipid 
accumulation in the arterial wall that might undergo oxidation over time (oxLDL), and 
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activation of several types of inflammatory cells (macrophages, T-cells, mast cells). That 
results in the formation of arterial plaques that may or may not be stable. Foam cells are lipid-
laden macrophages that undergo apoptosis and form the necrotic core of the arterial plaque. In 
susceptible plaques, the production of certain cytokines e.g. interferon-g (IFN-g) diminishes 
collagen synthesis and results in plaques with thin fibrous caps. Moreover, the production of 
proteases by inflammatory cells can disrupt the plaque’s fibrous cap leading to plaque rupture. 
A series of events characterized by platelet activation and thrombus formation follow, and 
may lead to arterial occlusion and a subsequent event of acute coronary syndrome (ACS) 
(such as myocardial infarction). On the other hand, stable plaques (less prone to rupture) 
continue to grow and cause reduction in the arterial blood flow, and can manifest as stable 
ischemic heart disease. 6-8 
With the need for new biomarkers for CVD and atherosclerosis, research has yielded new 
potential biomarkers such as high-sensitivity C-reactive protein (hsCRP), Brain natriuretic 
peptide  (BNP), anti-phosphorylcholine (Anti-PC), and Lp-PLA2. 9  
Lp-PLA2, also known as platelet activating factor acetyl hydrolase (PAF-AH), is a member of 
the phospholipase A2 (PLA2) family, group VIIA. According to the biochemical structure and 
properties of its members, Phospholipase A2 family is classified into 5 categories (secreted 
PLA2, cytosolic PLA2, Ca+ independent PLA2, lysosomal PLA2, and PAF-AH PLA2) divided 
in 15 groups. PLA2 enzymes hydrolyze the ester bond at the sn-2 position of phospholipids 
producing free fatty acids (FFA) and lysophospholipids. 10 
In the arterial wall, several phospholipids on LDL undergo oxidation altering their structure to 
yield oxLDL, which can be taken up by macrophages. OxLDL molecules contain different 
bioactive compounds that may include phospholipid products, sphingolipid products, free fatty 
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acid products, oxysterols, cholesteryl ester products, hydroxynonenal and malondialdehyde, 
and products of apolipoprotein B (ApoB) modiﬁcation. 11  
During the oxidation process, reactive oxygen species attack fatty acyl chains and cause them 
to undergo peroxidation to generate peroxides that provoke different signalling pathways that 
end up aggravating the inflammation process. 12 Unsaturated chains are more prone to 
oxidation than saturated fatty acids. Moreover, short-medium chained fatty acids are more 
prone to oxidation than long chained fatty acids. 13, 14 Therefore, polyunsaturated fatty acids 
(PUFA) commonly located on the sn2 position of the fatty acyl chain of the phospholipid are 
easier targets for oxidation due to the weak hydrogen-carbon bonds in methylene groups, and 
are believed to be the main source of various oxidized phospholipids. 12, 15, 16 
While PLA1 enzymes cleave fatty acyl chains at the sn1 position, oxidized phospholipids at 
the sn2 position trigger Lp-PLA2, yielding two main products: lysophosphatidylcholine (LPC) 
and nonesterified fatty acids (NEFA). 14 
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1.2 Biochemistry of Lp-PLA2 
1.2.1 Structure of Lp-PLA2 
Lp-PLA2 is a 45 KDa protein that consists of consists of 441 amino acids and doesn’t require 
Ca+ to perform its function. The crystal structure of Lp-PLA2 has been identified. 17 The 
catalytic site consists of a triad of serine, aspartate, and histidine, located on residues 273, 296, 
and 351 respectively, characterized Lp-PLA2 in a class separate from other PLA2 enzymes that 
lack the serine. 10 
Various cells secrete Lp-PLA2 such as macrophages, Kupffer cells, platelets, and mast cells, 
although it is likely that macrophages have the biggest role. Once Lp-PLA2 is secreted into the 
plasma, it binds to lipoproteins (mainly HDL and LDL) and circulates as an active enzyme. 
Some studies reported Lp-PLA2 distribution as approximately 80% on LDL and 20% on HDL, 
while others reported that it is around two-thirds on LDL vs. one third on HDL, and that Lp-
PLA2 mass in the plasma is more dependent on LDL-C levels. 18, 19 The interaction between 
Lp-PLA2 and LDL occurs between the N-terminus part of Lp-PLA2 and the C-terminus part of 
ApoB. 16 A previous study has shown that residue 205 on Lp-PLA2 is involved in that binding. 
On the other hand, it seems that Lp-PLA2 binds to HDL at three different sites, residues 113–
120, 192–204, 360–368, with 192–204 being the region where Lp-PLA2 binds to 
apolipoprotein A1 (ApoA1). 20  
Previous work has shown that Lp-PLA2 is associated with Lipoprotein a (Lp(a)) in the plasma, 
21, 22 while other studies have demonstrated the presence of a higher tendency of binding 
between Lp-PLA2 and small dense electronegative LDL subfraction (LDL-5) and very high-
density lipoprotein-1 subfraction (VHDL-1) in human plasma. 16, 23 A genome-wide 
association study by Thanassoulis et al recently discovered an association between Lp(a) 
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levels and aortic valve calcification and stenosis, suggesting a causal role for Lp(a) in valvular 
calcification. However, the relationship between Lp-PLA2 and Lp (a) is interesting. 24  
 
1.2.2 Lp-PLA2 and PAF  
When it was first discovered, and before joining the PLA2 family, Lp-PLA2 was initially 
known as Platelet activating factor acetylhydrolase (PAF-AH). PAF-AH was shown to 
hydrolyze the ester bond at the sn-2 position of PAF, producing LysoPAF and acetate. PAF-
AH was known for its potency in deactivating PAF. Today, it is classified as group VIIA, and 
is more commonly known as lipoprotein-associated phospholipase A2 (Lp-PLA2) due to its 
larger substrate specificity including PAF and oxLDL. 17 
First described in 1972, platelet-activating factor (PAF) is a phospholipid that is produced by 
various cell types (platelets, neutrophils, endothelial cells, and others) and acts as a 
communication mediator that transmits signals between cells. Similar to Lp-PLA2, the name 
PAF is somewhat misleading because it does not fully describe PAF biological activity. While 
it activates platelets, PAF has several physiological and pathological effects; it has shown to 
cause uterine contractions, bronchoconstriction, affect the vascular system (lowering blood 
pressure, reducing cardiac output, increasing vascular permeability), with a possible effect on 
the endocrine, gastrointestinal, and other systems. 25, 26 PAF has been linked to the 
inflammatory process as a proinflammatory molecule that binds to the PAF membrane 
receptor expressed on various cells, activates multiple signalling pathways (platelets, 
neutrophils, macrophages) that could trigger an inflammatory response that may include 
platelet aggregation, apoptosis, and vascular remodelling.  
 7 
Later, scientists discovered other phospholipids that have a resembling structure to PAF and 
function in a similar pattern as signalling molecules. The biologic effects of “PAF-like” 
molecules include platelet activation, PPAR activation, and stimulation of mitosis. Normal 
cells deactivate PAF and PAF-like molecules by intracellular PAF-AH, while extracellular 
PAF-AH (Lp-PLA2) also deactivates oxLDL in the arterial wall. 11, 27 
 
 
Figure 1. Hydrolysis of PAF by Lp-PLA2 (PAF-AH). Chemical structure for PAF was 
obtained from Lipid maps. 28  
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1.2.3 Substrate specificity  
When it comes to substrates, it seems that Lp-PLA2 has broad specificity. An exact substrate 
for Lp-PLA2 is not yet well identified despite several studies. Although PAF-AH, by 
definition, has higher affinity towards PAF, it is now known that Lp-PLA2 /PAF-AH 
substrates are not limited to PAF, but also include PAF-like molecules which are also 
phospholipids such as oxidized phospholipids, esterified isoprostanes, PEIPC and PC-
hydroperoxides. 15 
 
 
Figure 2. Hydrolysis of an oxidized phospholipid (POVPC) by Lp-PLA2. Chemical structure 
for POVPC was obtained from Lipid maps. 28 
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Min et al reported that diglycerides, triglycerides and acetylated alcohols are also potential 
substrates for Lp-PLA2. With an extensive possible structure of an oxLDL molecule, Lp-PLA2 
recognizes substrates that have a structure of a glyceride derivative with a hydrophobic chain 
at the sn-1 position and an ester at the sn-2 position. 29 It has also been suggested that Lp-
PLA2 residues 189-239 are responsible for substrate specificity. 21 
Despite the large number of potential substrates that could be targeted by Lp-PLA2, it seems 
that it targets certain phospholipids. Previous work has identified several truncated PC 
oxidation products as main substrates of Lp-PLA2. 14 
The specificity of the enzyme’s reaction can be linked to length of the fatty acyl on the sn2 
position of the phospholipid. Action of Lp-PLA2 seems to be more specific to fatty acyl chains 
of up to nine methylene groups. Phospholipids with longer chains (containing more than nine 
methylene groups) seem to be exempted from the action of PAF-AH, unless they are oxidized. 
14, 30  
 
1.2.4 Products of Lp-PLA2 and their biologic effects 
In order to neutralize PAF, Lp-PLA2 cleaves at the sn2 position of PAF to produce lysoPAF, a 
biologically inactive product, and acetate.  
A main product of Lp-PLA2 action on oxidized phospholipids is lysophosphatidylcholine 
(LPC), in the form of saturated and monounsaturated LPCs. LPC is produced in the plasma by 
2 other pathways: LCAT, and another phospholipase A2: sPLA2 which is classified as group 
IIa. With the production of LPC, a series of proinflammatory consequences escalate the 
inflammatory process and involves different cells. Those can be described by attracting 
 10 
monocytes, stimulating arachidonic acid release, upregulating cytokines and adhesion 
molecules, and induction of apoptosis. 31 
With the additional effect of certain enzymes that target LPC, lysophosphatidic acid (LPA) is 
produced, consequently leading to platelet activation. 11 LPC also acts as an intermediate 
product that could lead to the reproduction of PAF through the enzyme 
lysophosphatidylcholine acyltransferase (LPCAT), amplifying the inflammatory process. 27 
The other product of Lp-PLA2 action on oxidized phospholipids is free fatty acids (FFA). 
Those are also have been shown to be proinflammatory as they act as monocyte 
chemoattractants. 32 
 
1.2.5 Regulation of Lp-PLA2 
The PLA2G7 gene located on chromosome 6p21.1-p12 encodes Lp-PLA2. PLA2G7 is 
expressed in different tissues in the following decreasing order: thyroid, leukocytes, prostate, 
ovaries, lung, and others. 33, 34 Lp-PLA2 has been associated with the pathophysiology of 
several diseases and syndromes such asthma, atopy, dementia, coronary artery disease (CAD), 
heart failure, and stroke. 21  
To date, we do not have a complete understanding of Lp-PLA2 regulation. Taking in 
consideration its broad substrate specificity and controversial function, it seems that the 
regulation of Lp-PLA2 is multifactorial. Several studies concluded that Lp-PLA2 expression is 
dependent on cell differentiation and inflammatory mediators. 35, 36 A recent study 
demonstrated that serum amyloid A (SAA) significantly increases Lp-PLA2 expression in 
THP-1 cells and ApoE knock out mice. 37 Lp-PLA2 activity in the plasma can also be estrogen 
regulated. 38  
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As the main producers of Lp-PLA2, studies targeted Lp-PLA2 expression by macrophages in 
atherosclerotic plaques as well as the plasma. At the transcriptional level, Ferguson et al 
showed that Lp-PLA2 mRNA levels were elevated in macrophages (especially M1 
macrophages) but not in their precursors, the monocytes, and that expression increases post 
differentiation. Moreover, the study found Lp-PLA2 mRNA and protein levels to be higher in 
foam cells as compared to macrophages 36. Another study looked at the regulation of Lp-PLA2 
in macrophages and found that interferon gamma (IFN-γ) - a proinflammatory molecule - and 
lipopolysaccharide repressed Lp-PLA2 synthesis 39.  
Previous studies have shown a higher expression of Lp-PLA2 in aortic plaques 40. A recent 
study by Mahmut et al has shown a several fold increase in mRNA expression for Lp-PLA2 in 
patients with calcific aortic valve disease (CAVD) as compared to subjects with non-calcified 
aortic valves. The same study reported a higher plasma Lp-PLA2 activity in CAVD patients as 
compared to controls, and a higher Lp-PLA2 activity in stenotic valves than in non-
mineralized valves 41. We do not know much about its regulation in the plasma, although 
oxidized phospholipids have been shown to play a role in its regulation through several 
pathways.  
OxLDL appears to be a main player in the regulation of Lp-PLA2 expression. A study by 
Wang et al suggested that Lp-PLA2 upregulation was due to the presence of its substrates 
(oxidized PC species), but not its products. In the same study, the authors noticed that PAF 
didn’t exert a similar effect on Lp-PLA2 expression 35, while other studies showed that PAF.  
Finally, it is worthwhile mentioning that several studies have shown that despite Lp-PLA2 
being regulated by several pathways, it does not act as an acute phase reactant. 19, 36, 42 
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1.3 Lp-PLA2 animal models 
Because atherosclerosis is a complex process, choosing the suitable animal model depends on 
the specific aspect under study. 43 The mouse is probably not the best model for Lp-PLA2 and 
atherosclerosis studies, because their lipid profile is different from humans, and as a result the 
distribution of Lp-PLA2 is also different. Despite that fact, Lp-PLA2 and a specific Lp-PLA2 
inhibitor, Darapladib were studied in LDLR-deficient mice and homozygous ApoE-deficient 
mice. Both studies showed that Lp-PLA2 inhibition by Darapladib reduces inflammation and 
is associated with a decrease in plaque formation.  44, 45 
A study by Wilensky et al preferred a pig model to study Lp-PLA2 46, where the authors 
mention that the reasons for choosing the pig model rather than the mouse model were the 
similarity of plasma lipoprotein profile in pigs to humans, the similarity of Lp-PLA2 
distribution in pigs to humans, the better ability to study coronary lesions in those models 
compared to mice. In addition to those points, pig models had other advantages: anatomical 
resemblance of their cardiovascular system to humans, the resemblance of their atherosclerotic 
lesions to human lesions, their bigger size (bigger coronaries, bigger plaques), less need for 
genetic manipulation, and they can have atherosclerotic lesions even with chow diet (although 
slower) without the need for induction with high fat diet. In preclinical studies, the use of large 
animals (pigs, dogs, monkeys) is preferred for testing the efficacy of new agents such as 
Darapladib. The pig is often selected because of its similarities in terms of metabolism and 
cardiovascular system to that of man. Thus, the pig model appears a more suitable model for 
atherosclerotic studies compared to mice or rabbits. 43, 47 
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1.4 Lp-PLA2 and statins 
Statins have shown to reduce both the risk of cardiovascular events (by around 30%) and 
mortality. Those agents appear to play a role in limiting the atherosclerotic process by 
decreasing the levels of circulating LDL-cholesterol in the plasma, and possibly through other 
mechanisms, although not yet confirmed. Several studies show that Lp-PLA2 levels are 
significantly decreased after taking lipid-lowering medications. 22, 48 It is noticed that patients 
who were on high doses of statins (HMG-CoA reductase inhibitors) had reduced Lp-PLA2 
mass and activity of about 20% to 30%, with Atorvastatin being more effective than other 
statins. 19, 49, 50 In one of the mentioned studies, Atorvastatin did not affect Lp-PLA2 activity on 
HDL-C which confirms that statins do not influence Lp-PLA2 production, but rather increased 
LDL-C clearance. 51 Statins lower Lp-PLA2 levels. The role of the specific Lp-PLA2 inhibitor, 
Darapladib, has been questioned in clinical trials. 
 
1.5 Controversy of Lp-PLA2 function 
The role that Lp-PLA2 plays in CVD is still not very clear. To date, two main opposite roles 
for the enzyme in atherosclerosis have been suggested: anti-inflammatory and 
proinflammatory. One view holds that the substrates for Lp-PLA2 action, such as PAF and 
oxPC are known to be proinflammatory molecules, thereby emphasizing the antiatherogenic 
properties of Lp-PLA2. However, the by-products of Lp-PLA2 action are also proinflammatory 
molecules. 52 Several studies have shown high expression of Lp-PLA2 and LPC in unstable 
plaques. Moreover, they have shown correlation between increased Lp-PLA2 mass and 
activity and increased risk of CAD, stroke, and death. 40, 53 
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Overexpression of Lp-PLA2 and its products in atherosclerotic plaques could be to the fact that 
PLA2G7 is upregulated by several inflammatory mediators that are abundant in an 
inflammatory milieu. Moreover, in vivo studies have shown reduced inflammation with 
recombinant Lp-PLA2, which supports an anti-inflammatory role 21. A study conducted by 
Heart Protection Study Collaborative Group concluded that lipoproteins have high influence 
on the association between Lp-PLA2 and risk of coronary events. With adjustment for apoB 
levels, the association between the two became trivial 54. 
While elevated Lp-PLA2 plasma levels are associated with increased cardiovascular risk, 
HDL-associated Lp-PLA2 is associated with a lower cardiovascular risk, as observed in 524 
stable CAD patients in 3 year follow up study. That supports a more recent interpretation of 
those observations suggesting that Lp-PLA2 on HDL might participate in the antioxidant 
function of HDL and has an overall anti-inflammatory role, while Lp-PLA2 on LDL has a 
proinflammatory function 52.  
Taking different points in consideration, it is not clear whether the inhibition of Lp-PLA2 is 
beneficial in decreasing cardiac risk and mortality, as causality cannot be justified according to 
those associations. To reconcile this controversy, it is conceivable that the actions of Lp-PLA2 
maybe beneficial in one environment, but deleterious in another. Thus, we can postulate that 
the effects of Lp-PLA2 maybe beneficial in specific tissues e.g. plasma, but maybe deleterious 
in the plaque, where the molecules resulting from its action may then trigger secondary 
messengers, and further aggravate inflammation. 
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1.6 Epidemiologic studies of Lp-PLA2 
During the past decades, studies repeatedly explored the association between Lp-PLA2 and 
risk of CVD. In 2010, the Lp-PLA2 collaboration studies, a meta-analysis, evaluated the 
records of 79,036 subjects of 32 prospective studies and showed positive correlation between 
Lp-PLA2 and the risk of CAD, stroke, and death from vascular and nonvascular causes. 55 
A more recent study by Gonçalves et al demonstrated significant correlations between Lp-
PLA2, LPC species and LPA with several inflammatory mediators (IL-1β, IL-6, MCP-1, 
macrophage inflammatory protein-1β) and anti-inflammatory mediator (IL-10) in the 
atherosclerotic plaques in humans. 31 A previous study showed a higher carotid plaque 
expression of Lp-PLA2 and a higher concentration on LPC in symptomatic patients as 
compared to non-symptomatic patients undergoing carotid endarterectomy. 40 Vicker’s et al 
showed that Lp-PLA2 and oxLDL were highly correlated and expressed in areas with greater 
potential of plaque rupture artery (bifurcation and internal segments of the carotid artery). 56 
Two recent studies investigated Lp-PLA2 in the ACS setting and noticed strong positive 
correlations between Lp-PLA2 and LDL-C, ApoB with no association with hs-CRP and 
troponins. Meanwhile, studies have shown that the correlation between Lp-PLA2 and HDL-C 
was either weak or inverse. 19, 40, 57 
In the setting of familial hypercholesterolemia (FH), a recent study by Tellis et al that included 
53 patients and detected significant elevation in Lp-PLA2 mass and activity. 22 In addition, few 
case studies reported high plasma Lp-PLA2 activity in patients with Tangier’s Disease (TD), 
which is manifested by low levels of circulating HDL and defective cholesterol efflux caused 
by mutations in the ABCA1 gene, leading to higher risk of CVD 58. In a study that included 
almost 500 subjects, increased Lp-PLA2 levels were reported in heart failure and aortic 
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aneurysm patients. 59 In 48 patients with severe aortic stenosis without overt atherosclerosis, 
inverse correlation between Lp-PLA2 and aortic valve areas was reported, in addition to 
significant elevations in Lp-PLA2 levels. 60 
The controversy of Lp-PLA2 function extends to genetic studies. A relatively common 
PLA2G7 mutation of (V279), has been identified in several populations, and has shown to be 
more prevalent in East Asian populations (especially in Japan) than other Asian or European 
countries such as Turkey. This mutation results in partial or complete loss of function of Lp-
PLA2. Studies evaluating this mutation reported conflicting results, with more studies 
emphasizing a proinflammatory role for Lp-PLA2 in the carriers of this mutation. 61-63 
Finally, Brilakis reported that race and sex influence Lp-PLA2 levels, suggesting taking those 
factors in consideration when measuring Lp-PLA2 levels. 64 It also seems that diet and lifestyle 
measures such as smoking, weight and other factors might affect Lp-PLA2 activity. 65 Another 
recent study by Da Silva et al reported that Lp-PLA2 activity is influenced by glucose levels, 
HDL size and Apo B/Apo AI ratio in obese adolescents. 66 
 
1.7 Lp-PLA2 inhibition: the past, the present, and the future 
At time of discovery, Lp-PLA2 or better known at that time as PAF-AH was thought to have 
exclusive anti-inflammatory effects. PAF-AH studies showed significant reduction of severe 
inflammation in vivo and in vitro. It is ironic that what is known today as a proinflammatory 
enzyme was not very long ago known as an anti-inflammatory enzyme and was suggested as a 
treatment for inflammation. Studies suggesting a rather anti-inflammatory character of Lp-
PLA2 emphasize its role on degrading PAF and oxidized phospholipids on lipoproteins. At the 
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present time, the epidemiological and experimental data does not allow to solve the 
controversy on the protective or the proatherogenic role of Lp-PLA2.  
An argument can be made that despite the positive correlation between Lp-PLA2 and 
increased risk of CVD, the information present is not enough to imply causality. 55 The only 
way to show causality is by undergoing clinical trials.  
A normal level of Lp-PLA2 is <200 ng/mL, while a level of ≥223 ng/mL is considered high 
and current guidelines do not warrant Lp-PLA2 measurement as part of routine testing in 
patients with low risk for CAD. 67 
Phospholipase A2 inhibition presents an appealing therapeutic target. Two experimental 
phospholipase A2 inhibitors exist: Darapladib (Lp-PLA2 inhibitor) and Varespladib (sPLA2 
inhibitor). When we compare the two agents, we notice that they inhibit different PLA2 
isoforms. Darapladib uniquely inhibits Lp-PLA2; Varespladib inhibits several secreted PLA2 
isoforms (Group IIa, Group V and Group X), which have shown to have proinflammatory 
effects in atherosclerotic plaque formation. Similar to Lp-PLA2, they produce LPC and NEFA. 
18 In addition to Lp-PLA2 inhibition, Darapladib lowered the expression of 24 genes, several 
of which are inflammatory markers. 46 
The two agents (Darapladib, Varespladib) have been evaluated in several clinical trials, and in 
different in vitro and in vivo studies. Both have shown efficacy in inhibiting the enzymes in 
vitro, but lacked efficacy in humans. 44, 45, 68 In a phase II randomized clinical trial that sought 
to look at the effects of Darapladib in patients with stable coronary heart disease or coronary 
heart disease risk equivalent, positive correlation was present between LDL-C and Lp-PLA2 
activity, while a negative correlation between HDL-C and Lp-PLA2 was noticed. 49 In the 
phase II (Integrated Biomarker And Imaging Study– 2) IBIS-2 trial, more than 300 patients 
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with angiographically documented coronary heart disease and another risk factor were 
randomized to darapladib 160 mg/d or placebo for 12 months to examine the effects of 
Darapladib, where the results showed reduction in plaque areas and necrotic core in the 
treatment group as compared to the control group. 
IBIS-2 paved the road for Darapladib to undergo two large randomized phase III clinical trials. 
The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of 
darapLadIbTherapY) trial studied the effects of chronic treatment with Darapladib on the 
incidence of major adverse cardiovascular events (MACE) in high-risk patients with chronic 
CHD in 15,828 men or women with chronic coronary heart disease. STABILITY failed to 
meet the primary end points (relative risk reduction of 6%), despite some reductions in some 
of the secondary endpoints. 68, 69 The SOLID-TIMI 52 trial (The Stabilization Of pLaques 
usIng Darapladib-Thrombolysis In Myocardial Infarction 52) evaluated if Darapladib can 
lower the chances of having a cardiovascular event when treatment is started within 30 days 
after ACS. This study involved 13,000 men or women hospitalized for ACS. 70 Overall, 
Darapladib appears to be well tolerated by patients, and has not been reported to have adverse 
effects, except for minor effects like diarrhea and odour. 71 Nevertheless, SOLID-TIMI 52 
suffered the same fate as STABILITY, and failed to meet its primary end point. 72 
The other agent, Varespladib, did not have fruitful results. The phase III trial (Vista-16), which 
evaluated the safety and efficacy of Varespladib treatment on morbidity and mortality when 
added to Atorvastatin in 5,189 subjects with ACS, was unexpectedly terminated in March 
2012. Varespladib results were consistent in all the previous trials it underwent, but it 
stumbled in Vista-16 due to unknown reasons at present. 73, 74 
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Lp-PLA2 signifies a relation between oxidized lipoproteins (oxLDL) and inflammation and 
plaque susceptibility to rupture. It is highly possible that Lp-PLA2 is a physiological responder 
rather than a cause of inflammation. Will Lp-PLA2 have the same fate as hsCRP? The new 
results of the randomized clinical trials urge us to believe that Darapladib and other Lp-PLA2 
inhibitors may not see the light at the end of the tunnel. Until proven otherwise, Lp-PLA2 is of 
limited benefit in a clinical setting.  
  
 
 
Chapter II: Clinical Research 
 
 
Hypothesis, aims and objectives 
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Acute coronary syndromes are underlined by a long-term inflammatory state. Lp-PLA2 
functions by oxidizing modified phospholipids on the surface of the lipoprotein, an action that 
results in producing and accumulation of molecules (namely lysophosphatidylcholine and non-
esterified fatty acids) within the vessel wall, contributing to unstable plaque formation and 
aggravating inflammation. Multiple studies have observed an association between the role of 
Lp-PLA2 in plaque formation and increased risk of coronary artery disease, suggesting an 
inflammatory role for Lp-PLA2.  
The hypothesis was that the inflammatory milieu accompanying Acute Coronary Syndromes 
alters Lp-PLA2 levels and distribution (HDL and LDL). In the present study, we examined Lp-
PLA2 mass in patients with ACS acutely (within 48 hours) and again at ACS recovery (12 
weeks after their first presentation). Stable CAD and healthy control subjects were used for 
comparison.  
In the plasma, Lp-PLA2 is mainly distributed between LDL-C and HDL-C, with a greater 
percentage on LDL-C. A secondary objective was to compare the distribution of Lp-PLA2 in 
the plasma and among lipid fractions (HDL and LDL) in ACS acute and ACS recovery 
groups. To answer our research questions, we used two different separation techniques 
including ultracentrifugation (UTC) and high-performance liquid chromatography (HPLC).  
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Abstract 
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) might play a role in the 
formation of vulnerable atherosclerotic plaques. Its plasma distribution and mass in subjects 
with acute coronary syndrome (ACS) has yet to be characterized. 
Methods: We compared plasma levels of Lp-PLA2 in 24 patients within 48 hours of an ACS 
(acute) and 12 weeks after (recovery), in 26 patients with stable coronary artery disease and in 
10 normal healthy control subjects. Lp-PLA2 mass was determined using enzyme-linked 
immunosorbent assay.  
Results: The ACS patients (mean age 57 ± 8.7 years) had high-sensitivity C-reactive protein 
(hsCRP) levels of 30.46 ± 57.57 mg/L (ACS acute) vs. 1.69 ± 1.32 mg/L (ACS recovery). 
Plasma Lp-PLA2 levels were significantly higher in ACS acute subjects than in ACS recovery 
subjects (143.13 ± 60.88 ng/mL vs. 88.74 ± 39.12 ng/mL; P < 0.0001). Interestingly, stable 
coronary artery disease patients had higher Lp-PLA2 levels than ACS recovery patients 
(121.72 ± 31.11 ng/ mL vs. 88.74 ± 39.12 ng/mL; P = 0.0018). There was a strong correlation 
between Lp-PLA2 and low-density lipoprotein (LDL) cholesterol (LDL-C) (r = 0.709; P < 
0.0001) or changes in LDL (r = 0.449; P = 0.027), suggesting that the major determinant of 
plasma Lp-PLA2 is LDL-C. No significant correlations were observed between Lp-PLA2 and 
hsCRP or high-density lipoprotein (HDL) cholesterol. When separated using high-
performance liquid chromatography, > 65%-70% of Lp-PLA2 mass was within the 
apolipoprotein B-containing lipoprotein fraction, with approximately 30%-35% on HDL 
fraction, with no significant change in distribution between ACS acute and recovery. 
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Conclusions: Subjects with an ACS have markedly increased Lp-PLA2 levels acutely related 
to LDL-C levels. 
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Résumé 
Introduction: La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) pourrait jouer un 
rôle dans la formation de plaques athéroscléreuses vulnérables. Sa distribution plasmatique et 
sa masse chez les sujets ayant un syndrome coronarien aigu (SCA) a encore à être déterminée. 
Méthodes: Nous avons comparé les concentrations plasmatiques de Lp-PLA2 chez 24 patients 
dans les 48 heures d’un SCA (aigu) et dans les 12 semaines après (rétablissement), chez 26 
patients ayant une coronaropathie stable et chez 10 témoins en bonne santé. La masse de la 
Lp-PLA2 a été déterminée à l’aide de l’immunoabsorption par enzyme liée. 
Résultats: Les patients ayant un SCA (âge moyen de 57 ± 8,7 ans) ont eu des concentrations 
de protéine C réactive élevées de 30,46 ± 57,57 mg/l (SCA aigu) vs 1,69 ± 1,32 mg/l 
(rétablissement du SCA). Les concentrations plasmatiques de la Lp-PLA2 ont été 
significativement plus élevées chez les sujets ayant un SCA aigu que chez les sujets rétablis 
d’un SCA (143,13 ± 60,88 ng/ml vs 88,74 ± 39,12 ng/ ml; P < 0,0001). Fait intéressant, les 
patients ayant une coronaropathie stable ont eu des concentrations de la Lp-PLA2 plus élevées 
que les patients rétablis d’un SCA (121,72 ± 31,11 ng/ml vs 88,74 ± 39,12 ng/ml; P = 0,0018). 
Il existait une forte corrélation entre la Lp-PLA2 et le cholestérol à lipoprotéines de faible 
densité (C-LDL; r = 0,709; P < 0,0001) ou les changements dans le LDL (r = 0,449; P = 
0,027), ce qui suggère que le déterminant majeur de la Lp-PLA2 plasmatique est le C-LDL. 
Aucune corrélation significative n’a été observée entre la Lp-PLA2 et la protéine C réactive 
hautement sensible ou le cholestérol à lipoprotéines de haute densité (HDL). À la séparation 
par la chromatographie à haute performance, > 65%-70% de la masse de la Lp-PLA2 a été 
dans la fraction de la lipoprotéine contenant l’apolipoprotéine B, dont approximativement 30% 
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-35% sur la fraction de HDL, et aucun changement significatif dans la distribution entre le 
SCA aigu et le rétablissement du SCA. 
Conclusions: Les sujets ayant un SCA ont en phase aigue une augmentation significative des 
concentrations de la Lp-PLA2 liés aux taux de C-LDL. 
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Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker that is postulated to 
play a role in the formation of atherosclerotic plaques and might lead to plaque instability. 
Human Lp-PLA2 is encoded by the PLA2G7 gene. 75 It is produced by many cells, 
inflammatory (monocytes/macrophages, mast cells) and noninflammatory cells (liver Kupffer 
cells, platelets, erythrocytes), but it appears that macrophages are the main producers. 23 
Similar to other phospholipase A2 enzymes, Lp-PLA2 catalyzes the hydrolysis of the ester 
bond at the sn-2 position of phospholipids. Lp-PLA2 is bound to lipoproteins, predominantly 
to low-density lipoprotein (LDL) (approximately 80%), with a significantly smaller portion on 
high-density lipoprotein (HDL) (approximately 20%), 76 hence the name, Lipoprotein-
associated phospholipase A2. Originally described as platelet activating factor acetyl 
hydrolase, Lp-PLA2 cleaves the oxidized glycerophospholipid acetyl-glyceryl-ether-
phosphorylcholine in the sn-2 position to yield lysophosphatidylcholine (LPC) and an acetyl 
group. However, the substrate specificity of Lp-PLA2 is not well defined and it is thought to 
inactivate highly reactive oxidized phospholipids on lipoproteins. The products of the Lp-
PLA2 action, LPC and nonesterified fatty acids, are also known to be proinflammatory and to 
be involved in cell signalling.31 Lp-PLA2 thus represents a link between oxidized lipoproteins, 
inflammation, and plaque instability. In the arterial wall, LDL is modified into oxidized 
lipoproteins under oxidative stress, modifying some of the phospholipids on the LDL particle. 
The production of oxidized phospholipids activates LDL-bound Lp-PLA2. Lp-PLA2 
hydrolyzes those oxidized phospholipids (mainly oxidized phosphatidylcholine) and generates 
2 different molecules: LPC and nonesterified fatty acids. 23 
Lp-PLA2 is found in atherosclerotic plaques using immunohistology and its presence 
correlates with inflammatory cells and histological characteristics of plaque instability.77 A 
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meta-analysis of Lp-PLA2 in cardiovascular disease (CVD) reveals that Lp-PLA2 levels (mass 
and activity) are significantly associated with each other and with proatherogenic lipid 
markers. Lp-PLA2 levels are significantly related to CVD risk in a continuous and graded 
manner. 55 Because Lp-PLA2 levels predict future cardiovascular events, the measurement of 
Lp-PLA2 might be considered (Class IIb) in intermediate-risk asymptomatic adults. 78 
The effects of lipid-lowering therapies in Lp-PLA2 levels have been previously examined, 48, 79 
and the data show that statins significantly lower Lp-PLA2 levels. Albert et al showed that 
approximately 6% of the variability in the response of Lp-PLA2 to pravastatin was accounted 
for by a reduction in LDL cholesterol (LDL-C) levels. 80 In most reports, the effect of statins 
on Lp-PLA2 levels was significantly attenuated after adjusting for changes in LDL-C levels, 
reflecting the strong affiliation between these 2 substances in plasma. A recent study of Lp-
PLA2 levels in the first 3 days after an acute coronary syndrome (ACS) reveals that Lp-PLA2 
levels probably increase acutely, but that the subsequent change in levels correlate with the 
change in LDL-C. 57 Previous data have not shown any significant correlations between 
reductions in Lp-PLA2 levels and changes in HDL cholesterol (HDL-C) concentrations. 
 
The purpose of the present study was to examine plasma levels of Lp-PLA2 in ACS and its 
relationship to high-sensitivity C-reactive protein (hsCRP) and lipoprotein levels. Unlike C-
reactive protein, Lp-PLA2 does not seem to behave as an acute-phase reactant. 42 We 
hypothesized that the inflammatory milieu that is associated with an ACS might alter plasma 
levels of Lp-PLA2. The main objective of this study was to determine plasma levels and 
distribution of Lp-PLA2 at the time of an ACS (within 48 hours of onset of symptoms) and 
again, 12 weeks later, compared with patients with stable, chronic coronary artery disease 
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(CAD) (> 1 year after the event). We also determined the concentration of Lp-PLA2 in 
lipoprotein fractions. 
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Methods  
Study subjects.  
Patients, men and women aged between 18 and 80 years, were selected from the McGill 
University Health Center, Canada. Subjects within the ACS acute group were sampled within 
48 hours of symptom onset (n = 24) according to current diagnostic criteria. 81 The diagnosis 
of ACS was confirmed in a clinical assessment by a cardiologist (J.G.), including 
electrocardiographic changes (non-ST and ST segment elevation acute myocardial infarction), 
troponin I elevation, and the presence of CAD on coronary angiography. The same patients 
were resampled 12 weeks later (ACS recovery; n = 24). The 12-week time point was selected 
because most of the metabolic, lipoprotein, and inflammatory abnormalities have resolved by 
then. 82 As comparison groups, we also examined subjects with CAD and normal healthy 
control subjects (normals). The CAD group consisted of patients with chronic, stable CAD 
who had been followed in the lipid clinic for at least 11 year after a cardiovascular event, and 
the normals consisted of age-matched healthy subjects without CAD. These subjects had no 
CAD, documented using coronary angiography; all were awaiting elective aortic or mitral 
valve replacement or repair, and were not taking statin therapy. All subjects with stable CAD 
continued taking statins at the time of sampling, according to current guidelines and ethics 
requirements. 83-86 Exclusion criteria in the ACS patients included refusal to participate, 
inability to return for a 12-week follow-up visit, hemodynamic instability requiring 
vasopressor support, cardiac support devices, the need for urgent coronary artery bypass 
surgery, and the lack of documented atherosclerotic CAD, uncontrolled hypertension, 
triglycerides ≥ 5 mmol/L, severe obesity (body mass index ≥ 35), alcohol intake > 21 drinks 
per week, and presence of thyroid, hepatic, or renal disease. Subjects were excluded if they 
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had autoimmune disease or any chronic or acute infectious or inflammatory illness. The 
research protocol was reviewed and approved by the Research Ethics Board of the McGill 
University Health Center; all subjects gave written informed consent to participate. 
 
Plasma lipids, lipoprotein lipids, lipoprotein isolation, apolipoprotein B, hsCRP, and Lp-
PLA2 mass assays.  
Blood was collected from study subjects and control subjects using venipuncture; plasma was 
separated (2000g, 4 °C for 20 minutes) and multiple aliquots were frozen at -80 °C in 0.5-mL 
aliquots. Total cholesterol, triglycerides, and HDL-C were determined enzymatically and 
LDL-C was determined using the Friedewald formula. A sample of plasma (9 mL) was 
immediately processed for isolation of lipoproteins using ultracentrifugation (UTC). We 
isolated apolipoprotein B (apoB)-containing lipoproteins (LpB) in the < 1.09 g/mL density 
fraction and HDL using sequential UTC at a density between 1.09 g/mL and 1.21 g/mL using 
KBr as a salt. Isolated LpB and HDL fractions were then extensively dialyzed against 
phosphate-buffered saline, and total protein concentrations in these fractions were measured 
using a modified Bradford procedure (BioRad, Mississauga, Canada). Apolipoprotein A-1, 
apoB, and hsCRP concentrations were deter- mined using nephelometry (Behring 
Nephelometer 100 Analyzer). Lp-PLA2 concentrations (mass) were measured using a 
commercial Lp-PLA2 enzyme-linked immunosorbent assay (Quantikine ELISA, R&D 
Systems). 
Pools of plasma (125 uL) from the ACS acute and the ACS recovery group (n = 24) were 
separated into lipoprotein fractions using high-performance liquid chromatography (HPLC) 
with a Superose 6 10/300 GL column (GE Healthcare). A 150-mM NaCL mobile phase with a 
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flow rate of 0.4 mL/mL was used for the separation of the sample into seventy-two 400-uL 
HPLC fractions that were collected. Total cholesterol was determined enzymatically using the 
Infinity Cholesterol Liquid Stable Reagent (Thermo Electron Corporation) following the 
manufacturer’s instructions.  
 
Statistical analyses.  
Discrete variables are described as mean ± SD. For comparisons between ACS acute and ACS 
recovery, 2-tailed paired t tests with equal variance were selected. A P value of < 0.05 was 
considered significant. Pairwise comparisons between ACS acute, CAD, and Normals were 
considered significant at the 0.05 level. Pearson correlation coefficients were used to examine 
the relationship between Lp-PLA2 and LDL-C, apoB, hsCRP, HDL, and troponins. Linear 
regression was used to determine the effect of LDL-C-lowering on Lp-PLA2 levels. All 
statistical analyses were performed using the GraphPad Prism software V5.0 (La Jolla, CA). 
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Results  
Patient characteristics are summarized in Table 1. There were 24 patients in the ACS groups 
(19 men, 5 women, mean age 57 ± 9 years), 26 with chronic, stable CAD (24 men, 2 women, 
mean age 62 ± 9 years) and 10 Normals (10 men aged 57 ± 17 years). Mean hsCRP level in 
ACS acute subjects was 30.46 ± 57.57 mg/L and decreased to 1.69 ± 1.32 mg/L in ACS 
recovery, not significantly different from CAD (1.30 ± 1.22 mg/L) and Normals (1.85 ± 1.50 
mg/L). Peak troponin I level was 24.54 ± 36.29 ug/L in ACS acute (reference range, < 0.06 
mg/L), indicating acute myocardial injury. Plasma levels of LDL-C differed markedly 
between groups. Approximately half of the patients in ACS acute were taking various doses of 
statins at the time of sampling; the LDL-C in ACS acute was 2.35 ± 0.76 mmol/L. As per 
clinical practice guidelines, 83-86 ACS patients were put on a high-dose statin regimen 
(predominantly atorvastatin 80 mg or rosuvastatin 40 mg) and the LDL-C decreased to 1.52 ± 
0.43 mmol/L at 12 weeks (P < 0.0001 ACS acute vs. ACS recovery) (Table 1). CAD patients 
had a mean LDL-C of 2.03 ± 0.43 mmol/L. Normals were not using statins by design and the 
mean LDL-C was 3.19 ± 0.86 mmol/L. HDL-C levels were similar between ACS acute, ACS 
recovery, CAD, and Normals (Fig. 1). 
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Table 1. Study subject characteristics 
 
 
Characteristic ACS acute ACS recovery CAD Normals 
n 24 24 26 10 
Age, y 57 ± 9 57 ± 9 62 ± 9 57 ± 17 
Sex M 19/F 5 M 19/F 5 M 24/F 2 M 10/F 0 
hsCRP, mg/L 30.46 ± 57.57 1.69 ± 1.32 1.30 ± 1.22 1.85 ± 1.50 
Total cholesterol, mmol/L 4.19 ± 0.89 3.09 ± 0.68 3.80 ± 0.60 5.11 ± 1.04 
Triglycerides, mmol/L 1.82 ± 1.07 1.23 ± 0.60 1.48 ± 0.91 1.99 ± 1.22 
HDL-C, mmol/L 1.02 ± 0.24 1 ± 0.29 1.10 ± 0.28 1.14 ± 0.17 
LDL-C, mmol/L 2.35 ± 0.76 1.52 ± 0.43 2.03 ± 0.43 3.19 ± 0.86 
ApoB, g/L 0.85 ± 0.20 0.61 ± 0.12 0.75 ± 0.14 0.99 ± 0.20 
Lp-PLA2 in plasma, ng/ml 143.13 ± 60.88  88.74 ± 39.12 121.72 ± 31.11  188.70 ± 61.53 
 
Relevant P values are shown in Figures 1 and 2. 
ACS, acute coronary syndrome; ApoB, apolipoprotein B; CAD, coronary artery disease; F, 
female; HDL-C, high-density lipoprotein cholesterol; hsCRP, high- sensitivity C-reactive 
protein; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, Lipoprotein-associated 
phospholipase A2; M, male. 
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Figure 1. hsCRP and HDL-C (inset) levels in study subjects. Patients with an ACS (ACS 
acute) were sampled within 48 hours of presentation. The same patients were sampled 12 
weeks later (ACS recovery). Note the increase in hsCRP in the ACS acute group, compared 
with the recovery, CAD, and normal subjects. ACS, acute coronary syndrome; CAD, coronary 
artery disease; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-
reactive protein.  
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Figure 2. (A) Lp-PLA2 levels in the plasma of study subjects: ACS acute (n = 24), ACS 
recovery (n = 24), CAD (n = 26), and normal healthy subjects (n = 10). (B) Difference in Lp-
PLA2 mass between ACS acute and recovery. (C) Difference in LDL-C between the same 
groups. ACS, acute coronary syndrome; CAD, coronary artery disease; LDL-C, low-density 
lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2.  
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Plasma Lp-PLA2 levels were significantly increased in ACS acute (143.13 ± 60.88 ng/mL) 
compared with ACS recovery (88.74 ± 39.12 ng/mL; Fig. 2). CAD subjects had slightly higher 
levels than ACS recsovery (121.72 ± 31.11 ng/mL) and Normals had Lp-PLA2 levels in the 
normal range (188.70 ± 61.53 ng/mL), and not significantly higher than the ACS acute 
subjects (reference range, < 200 ng/mL). 67 In all patients, Lp-PLA2 levels decreased at 12 
weeks (Fig. 2B), and paralleled the decrease in LDL-C (Fig. 2C).  
UTC was used to separate LpB at a density of 1.006 g/L < LpB <1.09 g/L and HDL d = 1.09 
g/L < HDL < 1.21g/L. Only approximately 50% of Lp-PLA2 mass was recovered in the LpB 
fraction (Supplementary Figure 1A) (43% of total) and 3% in the HDL fraction (data not 
shown), suggesting that Lp-PLA2 is only loosely bound to lipoproteins and can be sheared off 
during UTC.  
We then separated lipoproteins using HPLC as shown in Figure 3A. The Lp-PLA2 distribution 
closely matched that of the LDL-C peak. A representative control HPLC analysis from a 
patient with high triglycerides (Fig. 3B) and high HDL-C (Fig. 3C) confirmed that Lp-PLA2 
resides predominantly within LDL. HPLC analysis of serum did not reveal a shift in the 
distribution of Lp-PLA2 between HDL and LDL. UTC, as previously stated, caused a 
significant loss of LDL- and HDL- associated Lp-PLA2, making quantification unreliable. 
When examining the correlations of Lp-PLA2 in all subjects, there was a strong and highly 
significant correlation between LDL-C and Lp-PLA2 (r = 0.709; r2 = 0.503; P < 0.0001), 
suggesting that half the variance in Lp-PLA2 can be explained by LDL-C levels (Fig. 4A and 
B). Similar data were obtained for total plasma apoB (r = 0.775; r2 = 0.6009; P < 0.0001). The 
change in Lp-PLA2 also correlated strongly with change in LDL-C between ACS acute and 
ACS recovery patients (n = 24; r = 0.449; P = 0.027) (Fig. 4B). These data suggest that LDL is 
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the major determinant of Lp-PLA2. In the 4 groups combined, the correlation between 
triglycerides and plasma Lp-PLA2 levels was r = 0.3868 (n = 84; P = 0.0003) (Fig. 4D). No 
significant correlation was observed between HDL-C and Lp-PLA2 (r = 0.181; P = 0.099) 
(Fig. 4E), between hsCRP and Lp-PLA2 (r = -0.023; P = 0.839) (Fig. 4F) or between troponin 
I and Lp-PLA2 in ACS acute (data not shown). When we examined groups separately, there 
was no correlation between hsCRP and Lp-PLA2 levels. The correlations for all variables are 
shown in Table 2. 
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Figure 3. Distribution of Lp-PLA2 mass. (A) Lp-PLA2 and cholesterol mass assays performed 
after HPLC separation of pooled plasma samples from ACS acute (n = 24) and ACS recovery 
(n = 24). Note that the distribution of Lp-PLA2 parallels that of LDL predominantly. (B) and 
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(C) show the distribution of Lp-PLA2 in 2 control subjects, a normo-lipidemic subject (B) and 
1 with elevated triglyceride levels (C), showing that Lp-PLA2 remains predominantly within 
the LDL-size fraction. ACS, acute coronary syndrome; HPLC, high-performance liquid 
chromatography; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated 
phospholipase A2; OD, optical density.  
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Figure 4. Correlations between Lp-PLA2 and LDL-C (A); change in LDL-C (B); Apo-B (C); 
HDL-C (D); triglycerides (E), and hsCRP (F). Apo-B, apolipoprotein B; HDL-C, high-density 
lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density 
lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2.  
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Table 2. Pearson correlation coefficients of Lp-PLA2 mass with cardiovascular risk factors in 
the study subjects. 
 
 
   Lp-PLA2 mass 
Factor r p 
      
Age, y    0.02612 0.8136 
BMI -0.2438 0.0351 
hsCRP, mg/L   -0.02256 0.8386 
Troponins *   0.1044 0.6355 
Total Cholesterol, mmol/L   0.7508      < 0.0001 
Triglycerides, mmol/L   0.3868 0.0003 
LDL-C, g/L   0.7096      < 0.0001 
Δ LDL-C, g/L ** 0.449 0.0277 
HDL-C, mmol/L 0.181 0.0993 
ApoB, g/L   0.7752      < 0.0001 
ApoA1, g/L   0.2643 0.0158 
 
 
ACS, acute coronary syndrome; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, 
body mass index; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-
reactive protein; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated 
phospholipase A2.  
* For ACS acute only (n = 24). 
** Between ACS acute and ACS recovery (n = 24). 
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Discussion  
In the present study, we showed that Lp-PLA2 in human is not an acute phase reactant and 
does not increase in acute inflammation. We also showed that Lp-PLA2 mass is closely related 
to LDL and LpB, with only a minor fraction within HDL. This has important implications if 
Lp-PLA2 is considered a therapeutic target. Lowering LDL-C with statins has a marked and 
proportional effect on Lp-PLA2 mass.  
A meta-analysis of the association between Lp-PLA2 mass or activity in plasma or serum 
shows that Lp-PLA2 levels predict recurrent cardiovascular risk. A small molecule, darapladib, 
is a specific inhibitor of Lp-PLA2 function and is currently undergoing clinical trials in 
patients with CAD. In the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib 
Therapy (STABILITY) trial, more than 15,000 patients with established CAD and another risk 
factor were randomized to darapladib 160 mg/d or placebo and a back- ground of appropriate 
lipid-lowering therapy with statins. 68 In the Stabilization of Plaques using Darapladib - 
Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial, 13,000 patients with an 
ACS have been randomized to darapladib or placebo. 70 Both trials are expected to be 
complete in 2013 and 2014 respectively. Importantly, both trials will be performed in patients 
treated to strict LDL-C goals. Considering the redundancy of phospholipases A2 - there are 15 
known phospholipase A2 groups comprising as many isoforms in humans 87; it is not certain 
that this approach will prevent CVD. 
A similar approach was used with varespladib, an inhibitor of the secretory phospholipase A2 
isoforms IIa, V, and X. In the Vascular Inflammation Suppression to Treat Acute Coronary 
Syndrome-16 Weeks (VISTA-16) trial, varespladib failed to meet its primary end point of 
CVD reduction. 70, 73, 74, 88 
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Previous groups have examined Lp-PLA2 levels in the early phase of an ACS. Dullaart et al 
reported that Lp-PLA2 levels in ACS did not differ from those found in patients with 
noncardiac chest pains. Interestingly, Lp-PLA2 levels were greater in a subset of patients with 
ST segment elevation myocardial infarction. The study did not control for baseline lipid 
values. 89 Ostadal et al recently reported that Lp-PLA2 levels were increased in the initial 
hours of an ACS, compared with in the following days. They reported an observation similar 
to ours, showing a relationship between LDL-C and Lp-PLA2 and a lack of correlation with C-
reactive protein and troponin I. 57  
The distribution of Lp-PLA2 on lipoproteins was demonstrated many years ago, 76, 90 and 
revealed that a minor percentage (approximately 20%) was associated with HDL. In a 
prospective study, Lp-PLA2 in plasma and within HDL was determined in more than 500 
patients who were followed for 3 years. Although Lp-PLA2 in plasma levels were associated 
with worse outcomes, HDL-associated Lp-PLA2 mass was associated with a lower risk 
(hazard ratio, 0.972; 95% confidence interval, 0.952-0.993; P = 0.010). An even more 
impressive effect of HDL-associated Lp-PLA2 activity on cardiac death (hazard ratio, 0.689; 
95% confidence interval, 0.496-0.957; P = 0.026) was observed. 52  
The biology of Lp-PLA2 is only partly understood. Initially described as a platelet-activating 
factor (or 1-O-alkyl-2-acetyl-sn- glyceryl-3-phosphorylcholine) acetylhydrolase, its 
physiological role remains uncertain. It is possible that on LDL, Lp-PLA2 hydrolyzes oxidized 
phospholipids, generating LPC and oxidized lipids that are deleterious within an 
atherosclerotic plaque, whereas when present on HDL, it neutralizes platelet-activating factor 
and prevents platelet activation. Lp-PLA2 is present in atherosclerotic plaques, as shown using 
immunohistochemistry and its presence correlates with histological features of plaque 
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instability. 77 However, a causal relationship between Lp-PLA2 presence and plaque rupture 
has not been yet demonstrated. Thus, for the present time, the measurement of Lp-PLA2 mass 
should be considered a biomarker of atherosclerosis. Its pathological role and potential as a 
therapeutic target must be further studied.  
The main conclusion of the present study is the very close correlation between LDL-C and Lp-
PLA2 levels, suggesting that statin therapy might contribute to the reduction in cardiovascular 
events in a pleiotropic fashion. Our study has several limitations. The sample size was 
relatively small. We were careful to compare the same patients in ACS acute and ACS 
recovery groups and to match CAD patients and Normals for age and HDL-C levels. We did 
not determine Lp-PLA2 activity; however, previous studies have shown a strong correlation 
between mass and activity. 55, 90 Importantly, the quantification of Lp-PLA2 within lipoprotein 
fractions is limited by the technique used. We have shown that UTC causes loss of Lp-PLA2 
mass, most likely because of the shear stress engendered. More problematic is the 
quantification of Lp-PLA2 within the HDL range. It is extremely difficult to separate HDL 
particles from plasma proteins using HPLC. Thus, “lipoprotein-free” Lp-PLA2 (i.e. not bound 
to lipoproteins is very difficult to quantify). In our previous study of HDL proteomics in ACS, 
Lp-PLA2 was not identified as 1 of the 70 proteins within HDL. 91 
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4.1 Discussion and conclusion 
The purpose of the study was to investigate the role of Lp-PLA2 in patients with acute 
coronary syndromes. Acute coronary syndromes are characterized by systemic inflammation, 
as evidenced by hsCRP levels and serum amyloid levels. Because of the importance of Lp-
PLA2 in the pathogenesis of atherosclerosis, and the development of agents that block Lp-
PLA2, we undertook this study to examine whether Lp-PLA2 levels vary in patients with an 
acute inflammatory state. To further explore the relationship between Lp-PLA2 and ACS 
events, we hypothesized that Lp-PLA2 levels would be elevated in acute coronary syndromes 
acutely, reflecting an overall inflammatory state.  
We measured the levels of Lp-PLA2 in patients with acute coronary syndromes within 48 
hours of their first presentation, and three months later once the inflammation has subsided. 
For comparison, we used control patients who were not on medications, and have no evidence 
of coronary artery disease on coronary angiography (those patients were selected for elective 
valvular replacement but no bypass surgery). A second control group of stable chronic 
coronary artery disease patients at least one year post cardiac event were selected.  
Subjects with ACS in the acute state exhibited a significant increase in Lp-PLA2 levels 
compared to ACS recovery. Lp-PLA2 levels were higher in stable chronic coronary artery 
disease patients than in subject with ACS in the recovery phase. A strong correlation was 
noted between Lp-PLA2 and LDL-C, and the difference in Lp-PLA2 levels strongly correlated 
with the difference in LDL-C levels in ACS acute and ACS recovery groups. Those 
correlations suggest that LDL-C levels have a major influence on Lp-PLA2 levels, and might 
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partly explain the reduction of Lp-PLA2 levels in the ACS recovery group, as Lp-PLA2 
resided mostly within LDL. When we compared the distribution of Lp-PLA2 among the 
plasma and different lipid fractions (HDL, LDL) in ACS acute and ACS recovery, we did not 
notice any difference in Lp-PLA2 distribution between HDL and LDL. It is important to 
mention that there was lack of correlation between Lp-PLA2 and hsCRP and troponin I. 
The hypothesis was not confirmed as Lp-PLA2 levels went down dramatically along with 
LDL-C levels, and this is probably is due to the fact the Lp-PLA2 travels predominantly with 
LDL. The main conclusion of the study was that the significant increase in Lp-PLA2 levels in 
subjects with an acute ACS, an increase that was mostly attributed to increased LDL-C in 
those subjects.   
The role that Lp-PLA2 plays in cardiovascular disease is still unclear. However, there have 
been new insights on the role of Lp-PLA2 in plaque formation. To better understand that role, 
Fanning et al induced Diabetes mellitus (DM) and hypercholesterolemia (HC) 37 pigs. 
Abdominal aortic plaques exhibited more atherosclerosis, greater plaque area (4.4 fold), more 
calcifications and higher risk for intraplaque haemorrhage as compared to plaques in the 
coronary arteries. When Lp-PLA2 inhibition was induced in 20 pigs, Darapladib significantly 
reduced intraplaque haemorrhage in the abdominal aortic plaques, with no significant effect on 
the coronaries. However, the study reported greater plaque reduction in the coronaries as 
compared to the abdominal aortic plaques (2.9 fold) with Darapladib treatment. The reduced 
effect of Darapladib on plaque reduction in the abdominal aorta compared to coronaries 
suggests site-specific effect of Darapladib on plaque reduction. This finding also suggests that 
Lp-PLA2 was more involved in the inflammatory pathways that led to plaque formation in the 
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coronaries. Site-specific results of Darapladib might reduce the favourability of Darapladib 
use as potential treatment for atherosclerosis. 92 
While studies demonstrated encouraging results for Lp-PLA2 inhibition in animal models, 
clinical trials had disappointing outcomes. The results from two large clinical trials 
(STABILITY and SOLID-TIMI 52) show that Lp-PLA2 inhibition by Darapladib did not 
change patient outcome, questioning the potential benefit of Lp-PLA2 inhibition. 68, 70 
The enthusiasm for measuring Lp-PLA2 as a biomarker of risk has dropped markedly due to 
two reasons. The first reason would be the finding that Lp-PLA2 is strongly associated with 
LDL-C, and that statins can bring Lp-PLA2 levels down markedly. The second reason would 
be that two trails of agents that specifically block Lp-PLA2 have had neutral results. While 
those agents were well tolerated, they did not change cardiovascular outcomes.  
In other cardiovascular diseases such as stroke, Lp-PLA2 did not encounter much success. 
Although regarded as a predictor of risk in vascular diseases including acute coronary 
syndrome and stroke, Lp-PLA2 has not shown to have an additional prediction value. A study 
by Riba-Llena et al included 921 stroke-free subjects to assess whether novel biomarkers such 
as Lp-PLA2 could be a valuable addition to standard biomarkers such as troponin I and brain 
natriuretic peptide (BNP) in predicting silent brain infarcts. Lp-PLA2 activity was associated 
with silent brain infarcts in women in an independent fashion, but unfortunately Lp-PLA2 
failed to add any value in disease prediction in that specific population. In men, Lp-PLA2 
activity did not show significant association with silent brain infarcts, despite adjusting for 
several factors including age, blood pressure, cholesterol levels and statin therapy. 93 
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Another study by Tai et al studied Lp-PLA2 in the context of brain ischemia. Lp-PLA2 mass 
and activity were measured in 100 subjects, where 58 subjects of the total population suffered 
ischemic events (transient ischemic attack and stroke). Lp-PLA2 did not show statistical 
significance in subjects with ischemia compared to non-ischemic subjects, and did not exhibit 
diagnostic value in acute brain ischemia. 94 
There are 15 phospholipase A2  (PLA2) isoforms, and the by-products from these reactions, 
which include highly oxidized fatty acyl chains may themselves be toxic to the vascular 
endothelial cells, and the resulting product (lyso phospholipids) may be involved in signalling. 
It is therefore not clear whether the activity of this enzyme is beneficial in terms of 
cardiovascular disease or not, and the body of knowledge does not allow us to make a firm 
commitment. Another interesting point to mention is that the biological system seems highly 
redundant because of the multiplicity of lipases with various specificities in plasma.  
A Mendelian randomization meta-analysis by Holmes et al analysed 19 general population 
studies and 10 acute coronary syndrome studies in an attempt to investigate a possible causal 
relationship between secreted PLA2 (sPLA2-IIA mass) and major vascular events. Holmes et 
al could not establish a causal relationship, and concluded that secretory PLA2 inhibition may 
not be of clinical benefit in preventing cardiovascular events. 95 
Another genetic study by Polfus et al performed exome sequencing for 6325 subjects to 
evaluate a possible causal effect of Lp-PLA2 on the incidence of coronary disease. Lp-PLA2 
activity was strongly associated to one variant (rs34159425), which was described by the 
authors as a variance of low frequency that has no significant association with coronary 
events. The researchers concluded the unlikely presence of a casual relationship between Lp-
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PLA2 and the incidence of coronary disease. 96 Based on the two previous studies, Lp-PLA2 
was not found to increase cardiovascular disease. Both studies reduce the possibility that Lp-
PLA2 has a causal link to cardiovascular disease.  
To conclude, current evidence indicates that Lp-PLA2 is involved in the pathophysiology of 
acute coronary syndrome and cardiovascular diseases in general, with no causal relationship 
identified. Therefore, current role of Lp-PLA2 in clinical therapy and as a standard biomarker 
is incomplete with lack of supporting evidence.   
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4.2 Future work 
Although the present study is limited by a relatively small number of patients, the results 
obtained are important. Thus, we will aim to increase sample size in future work. The loss of 
Lp-PLA2 mass in Ultracentrifgation due to high speed involved in the nature of this technique 
is another point to be addressed. Therefore, we might include additional techniques for sample 
preparation in our future work, such as isolating HDL by polyethyleneglycol (PEG), thus 
avoiding losing Lp-PLA2 mass. Moreover, additional experiments assessing Lp-PLA2 role 
could be added, ideally measuring Lp-PLA2 activity as an indicator of Lp-PLA2 function. 
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Annex 1 
 
 
 
 
 
Supplementary Figure 1. (A) Lp-PLA2 mass in the apoB-containing lipoprotein fraction 
(LpB) obtained by UTC. Note the results closely parallel those obtained in Figure 2. (B) Lp-
PLA2 mass in high-density lipoprotein (HDL) fraction. Measurements performed in ACS 
acute (n=24), ACS recovery (n=24), Stable CAD (n=26), and normal healthy subjects (n=10). 
Note the different units for both the LpB and HDL fractions reflecting the volumes and 
concentrations obtained after UTC and sample dialysis. 
